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Abstract  
BACKGROUND: Obesity is associated with an increased risk of developing hyperinsulinemia, 
dyslipidemia, hypertension, premature atherosclerosis, and coronary artery disease in the future.  
AIM: This study is designed to assess the relationship between serum adiponectin, asymmetric 
dimethylarginine (ADMA), and lipid profile among Egyptian overweight and obese children. 
METHODS: This cross sectional case control study included 40 selected pre-pubertal overweight 
and obese children, 24 girls (60%) and 16 boys (40%) aged between 5 to 13 years (8.85 ± 2.7 
years), from new cases attending the National nutrition institute clinic during 2013. Forty apparently 
healthy children of matched age and sex were recruited as a control group.  
RESULTS: Obese group showed highly significant higher levels of serum ADMA, triglycerides, and 
total cholesterol compared with healthy controls (P < 0.000 in all). However, serum adiponectin 
levels were highly significant lower in obese children compared to healthy controls (P < 0.000). 
Serum ADMA showed significant positive correlations with height, serum total cholesterol and 
serum triglycerides levels and significant negative correlation with the body mass index and weight 
for age z score.  Serum adiponectin showed significant negative correlations with BMI, weight, and 
weight for age z score and significant positive correlation with serum triglycerides. By linear 
regression analysis; serum adiponectin, and serum triglycerides levels were significant predictors of 
high serum ADMA level (p =0.045 and 0.015 respectively). BMI, weight, height and serum 
triglycerides were significant predictors of low serum adiponectin levels (p = 0.005, 0.022, 0.026 
and 0.015 respectively). 
CONCLUSIONS: Our results revealed that ADMA, Adiponectin and lipid profile can be considered 
as predictive biomarkers in prediction and prevention of atherosclerotic risk in the future among 
overweight and obese Egyptian children.   
 
 
 
 
Introduction 
           Obesity in children is the most prevalent 
nutritional disorder among children and adolescents 
worldwide. Approximately 21-24% of American 
children and adolescents are overweight, and another 
16-18% is obese [1]. The prevalence and magnitude 
of obesity in the children and the adolescents have 
increased dramatically in the developing countries 
over the last 20–30 years, that could be attributed to 
the complex interactions between genes, dietary 
intake, physical activity, and the environment [2]. 
 Obesity in children is now so endemic that 
many countries are reporting a prevalence of 25% or 
higher [3]. Obese children are at a greater risk of 
insulin resistance, hyperinsulinemia, glucose 
intolerance, type 2 diabetes, hyperlipidemia, 
hypertension, premature atherosclerosis, and 
coronary artery disease in the future [4]. Adiponectin 
is an adipocyte secreted hormone that influences the 
body's response to insulin, and regulates the lipids 
and glucose metabolism through increase fatty acid 
oxidation and improve insulin sensitivity [5]. 
Adiponectin also has anti-inflammatory effects and 
anti-atherosclerotic effects on the endothelial walls of 
blood vessels [6]. It plays a role in the suppression of 
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the metabolic derangements that may result in 
obesity, atherosclerosis, and cardiovascular risk. High 
blood levels of adiponectin are associated with a 
reduced risk of heart attack [7]. Adiponectin regulation 
is altered in obese children, and its serum level is 
inversely correlated with the body fat percentage in 
children [8]. 
Nitric oxide (NO) is the most potent 
endogenous vasodilator molecule released from the 
endothelium against atherosclerosis. Accordingly, 
impairment of NO synthesis bioactivity may increase 
the risk of vascular disease [9]. Asymmetric 
dimethylarginine (ADMA) is an endogenous inhibitor 
of nitric oxide synthase that has been linked to 
endothelial dysfunction and atherosclerosis in the 
general population [10]. Endothelial dysfunction is one 
of the early abnormalities observed in the 
pathogenesis of atherosclerosis, and cardiovascular 
disease [11]. Gruber and his colleagues suggested 
ADMA to be a sensitive independent marker and even 
an initiator of endothelial dysfunction. Elevated ADMA 
levels have been shown to be associated with 
atherosclerosis, hyperlipidemia, and hypertension 
[12]. Therefore, the aim of this study is to assess the 
relationship between serum asymmetric 
dimethylarginine, adiponectin levels, and lipid profile 
among overweight and obese Egyptian children. 
 
Material and Methods 
 Patients 
This cross sectional case control study 
included 40 randomly selected overweight /obese 
children, aged 5 to 13 years, from new cases 
attending the National nutrition institute outpatient 
clinic during 2013. The inclusion criteria for selection 
were pre-pubertal overweight & obese children with 
current age between 5 and 13 years. Overweight & 
obese children were defined using BMI for age and 
sex charts according to standardized methods of the 
World Health Organization (WHO) [13]. Children 
having obesity syndromes, or taking medications 
associated with weight change as glucocorticoid 
therapy were excluded from the study. None of the 
participants had chronic illness as cardiovascular or 
endocrine disease as type 1 or 2 diabetes, 
hypothyroidism, and Cushing's disease. Forty 
apparently healthy children of matched age and sex 
were recruited as a control group. A written informed 
consent was obtained from the study participants’ 
parents. The study was conducted in accordance to 
ethical procedures and policies.  
 
Methods 
Each child was subjected to a complete 
physical examination and anthropometric measures. 
Weight was taken using a digital scale (Seca, 
Hamburg, Germany) to the nearest 0.1 kg. Height was 
measured using a Seca 225 stadiometer to the 
nearest 0.1 cm with the children dressed in minimal 
clothes and without shoes [14]. 
Overweight & obese children were defined 
using BMI for age and sex charts according to 
standardized methods of the World Health 
Organization (WHO) [13]. Normal weight is defined as 
BMI percentile between the 5th and < 85th 
percentiles, overweight as BMI percentile between the 
85th and 95th percentiles, and obesity as weight for 
age percentile > 95
th
 percentile. Body mass index 
(BMI) was calculated as the body weight in kilograms 
divided by the square of height in meters (kg/m
2
) to 
classify overweight and obese children. A body mass 
index below 18.5 means that the child is underweight, 
18.5 to 24.9 means that the child fall in the normal 
range, 25.0 to 29.9 means child is overweight and a 
score of 30.0 and higher means the child is obese. 
Other growth parameters including weight and height 
for age percentiles and z scores were also calculated.  
Venous blood samples were drawn after a 12-
hr overnight fasting. After clot formation, centrifuge 
samples at 2000 x g for 10 minutes. Removed serum 
was stored at −80°C. Serum ADMA was determined 
by Sandwich- enzyme linked immunosorbent assay 
(ELISA) as the method using kit provided from 
Immundiagnostik AG, Bensheim, Germany, according 
to the method described by Nijveldt et al. [15].  
Serum adiponectin was determined by 
enzyme linked immunosorbent assay (ELISA) method 
using AssayMax Human Adiponectin ELISA Kit 
(Millipore, St. Charles, MO, USA), in which the mean 
of the minimum detectable concentration was 0.5 
ng/mL. Intra- and inter assay coefficients of variation 
were 4.2 % and 7.3 % respectively. The AssayMax 
Human Adiponectin ELISA Kit is designed for 
detection of adiponectin in human serum. This assay 
employs a quantitative sandwich enzyme 
immunoassay technique that measures adiponectin in 
less than 4 hours.  
Serum triglycerides were determined 
according to the colorimetric method of Fossati and 
Principe [16] using the Biocon enzymatic kit. Total 
cholesterol was determined colorimetrically using a 
Stanbiolaboratory kit (USA), according to the method 
of Richmond, [17]. 
 
Statistical analyses 
Statistical analyses were performed using the 
SPSS statistical package software for Windows 
version 20 (SSPS Inc, Chicago, USA). Parametric 
variables are expressed as the mean ± SD. 
Differences between parametric variables among the 
2 groups were evaluated using 2-tailed unpaired t-
test. Pearson’s correlation coefficients were used to 
evaluate correlations between the data exhibiting 
Hameed et al. Asymmetric Dimethylarginine, and Adiponectin as Predictors of Atherosclerotic Risk 
_______________________________________________________________________________________________________________________________ 
_______________________________________________________________________________________________________________________________ 
OA Maced J Med Sci. 2014 Jun 15; 2(2):209-214.                                                                                                                                                                         211 
 
parametric distribution. Linear logistic regression 
analysis was performed to examine the relationship 
between serum ADMA and adioponectin levels with 
anthropometric measures and lipid profile. P value 
<0.05 was considered significant difference and 
p<0.005 was considered highly significant difference. 
 
Results  
A total of forty obese children aged between 5 
to 13 years (mean 8.85 ± 2.7 years) were studied. Out 
of them, 21 children (52.5%) were obese and 19 
children (47.5%) were overweight. They were 24 girls 
(60%) and 16 boys (40%) with female to male ratio 
1.5:1. The mean weight and BMI of the obese group 
was significantly higher compared with those of the 
control group (P < 0.005), however no significant 
difference was present with respect to height. The 
mean weight for age percentile and Z score of the 
overweight and obese group was significantly higher 
compared with the controls (P < 0.005). The mean 
height for age percentile and Z score of the 
overweight and obese group was significantly higher 
compared with the controls (P < 0.005) as shown in 
(Table 1). 
Table 1: Anthropometric measurements of overweight/obese 
and control groups. 
Variables 
Overweight / obese 
group 
(n=40) 
Control 
group 
(n=40) 
 
t 
 
P 
value 
Mean ± SD Mean ± SD 
Weight (kg) 45.62 ± 13.85** 27.18 ± 6.7 8.88 0.000 
Height (cm) 134.4 ± 13.93 131.7 ± 16.17 1.91 0.063 
BMI (kg/m2) 25.12 ± 6.22** 15.24 ± 2.55 9.52 0.000 
Weight/age 
percentile 
83.9 ± 17.17** 36.05 ± 10.6 19.03 0.000 
Height/age 
percentile 
67.18 ± 25.84** 44.9 ± 14.18 4.622 0.000 
Weight/age Z score 3.34 ± 2.72** -.33 ± 0.19 8.87 0.000 
Height/age Z score 1.44 ± 0.56** -.28 ± 0.29 3.47 0.001 
 
*Significant difference at p<0.05; **highly significant difference at p<0.005. 
 
Our patients showed highly significant higher 
levels of serum ADMA, triglycerides, and total 
cholesterol compared with healthy controls (P < 0.000 
in all). However, serum adiponectin levels were highly 
significant lower in obese children compared with 
healthy controls (P < 0.000) as shown in (Table 2). 
 
Table 2: Laboratory findings of overweight / obese and control 
groups. 
 
Variables 
Overweight/obese  
group 
(n=40) 
Control group 
(n=40) 
 
t 
 
P value 
Mean ± SD Mean ± SD 
Serum ADMA  
(μmol/L) 
4.83 ± 0.81** 2.15  ± 0.45 20.51 0.00 
Serum adiponectin 
(μg/mL) 
7.11 ± 1.44** 11.04 ± 1.4 -9.52 0.00 
Serum  cholesterol 
(mg/dl)  
128.42 ± 20.37** 68.5 ± 16.69 12.69 0.00 
Serum triglycerides 
(mg/dl) 
166.95 ± 22.79** 64.9  ± 13.56 23.81 0.00 
 
**Highly significant difference at p<0.005. 
Serum ADMA showed significant positive 
correlations with height, serum total cholesterol and 
serum triglycerides levels and significant negative 
correlation with the body mass index and weight for 
age z score.  Serum adiponectin showed significant 
negative correlations with BMI, weight, and weight for 
age z score and significant positive correlation with 
serum triglycerides, (Table 3). 
Table 3: Correlations between serum ADMA, and adiponectin 
levels, versus anthropometric measures and lipid profile 
among studied children. 
Variables Serum ADMA Serum Adiponectin 
BMI -0.329
*
 -0.377
*
 
Height 0.407
**
 -0.141 
Weight -0.04 -0.347
*
 
Weight for age z score -0.26* -0.29* 
Serum triglycerides 0.371
*
 0.31
*
 
Serum total cholesterol 0.317* -0.046 
*Significant difference at p<0.05; **highly significant difference at p<0.005. 
 
By linear regression analysis; serum 
adiponectin, and serum triglycerides levels were 
significant predictors of high serum ADMA level (at p = 
0.045 and 0.015 respectively), (Table 4). 
Table 4:  Linear regression analysis of predictors of high 
serum ADMA levels. 
Model 
Unstandardized Coefficients 
Standardized 
Coefficients t Sig. 
B Std. Error Beta 
1 
(Constant) 4.993 1.619  3.084** 0.004 
Serum adiponectin -0.183 0.087 -0.324 -2.090* 0.045 
Serum triglycerides 0.016 0.006 0.447 2.589* 0.015 
a) Dependent Variable: ADMA 
b) Predictors: (Constant),  Adiponectin, Serum triglycerides 
*Significant difference at p<0.05; **highly significant difference at p<0.005. 
 
By linear regression analysis; BMI, weight, 
height and serum triglycerides were significant 
predictors of low serum adiponectin levels (at p= 
0.005, 0.022, 0.026 and 0.015 respectively), (Table 5). 
Table 5: Linear regression analysis of predictors of low serum 
adiponectin levels. 
 
Model 
 
Unstandardized Coefficients 
Standardized 
Coefficients 
 
t 
 
Sig. 
B Std. Error Beta 
1 
(Constant) 34.010 10.187  3.339** 0.002 
Weight 0.297 0.123 2.841 2.412* 0.022 
Height -0.193 0.082 -1.854 -2.342* 0.026 
BMI -0.702 0.233 -3.018 -3.013** 0.005 
Serum triglycerides 0.030 0.012 0.472 2.594* 0.015 
a) Dependent Variable: Adiponectin 
b) Predictors: (Constant),  wt, ht, BMI and Serum triglycerides 
*Significant difference at p<0.05, **highly significant difference at p<0.005. 
 
Discussion  
During the last three decades, obesity has 
emerged worldwide as an epidemic affecting all ages 
and socioeconomic levels [18]. The National Health 
and Nutrition Examination Survey (NHANES) reported 
that the prevalence of obesity is increasing in all 
pediatric age groups, in both sexes, and in various 
ethnic and racial groups [19].  
Due to the increasing trends toward more 
energy dense diet and sedentary lifestyles as 
elsewhere in different parts of the world, higher 
percentages of obesity among Egyptian children were 
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reported. Hassan et al., found that the prevalence of 
+obesity among primary school children was 6% and 
of overweight was 10.5% in a cross-sectional survey 
that comprised 2083 children, from two primary public 
schools situated in Giza governorate [20]. El Derwi et 
al. reported that 34.2% of school children were obese 
in the Fayoum governorate in Egypt [21].  
In our study, a total of forty children aged 
between 5 and 13 years (mean 8.85 ± 2.7 years) were 
studied. Out of them, 21 children (52.5%) were obese 
and 19 children (47.5%) were overweight. They were 
24 girls (60%) and 16 boys (40%) with a female to 
male ratio 1.5:1. This higher percentage of overweight 
and obesity in girls is in accordance to the study 
conducted by Shaheen et al., who reported that the 
National Egyptian levels of obesity have been 22.9% 
in girls and 18% in boys [22]. Hassan et al., also found 
higher percentage of obesity in girls among school 
children [20]. Moreover, El Derwi et al. reported that 
obesity among school children is significantly more 
prevalent among girls (39%) than boys (30.5%), [21].   
To our best knowledge, this study is 
considered to be the first clinical study that carried out 
to examine the relationships between serum 
asymmetric dimethylarginine (ADMA), serum 
adiponectin levels and lipid profile among overweight 
and obese Egyptian children.  
Faith et al. reported that ADMA is a predictive 
factor for the progression of carotid artery intima-
media thickness in obese adults. Elevated ADMA 
levels have been suggested as having a role in 
cardiovascular system disorders [23]. 
Our present study demonstrated highly 
significant rise in serum ADMA levels among 
overweight and obese children compared to healthy 
controls with insignificant differences in the mean 
serum ADMA concentrations between males and 
females (p > 0.05). This is in consistent with the 
findings reported by Faith et al. and Teplan et al., who 
reported higher, level of serum ADMA in obese 
compared to healthy controls with insignificant 
differences as regards gender in the mean serum 
ADMA concentrations [23, 24]. 
Strangely enough our current study 
demonstrated that serum ADMA levels showed 
significant inverse correlation with anthropometric 
measures of adiposity as BMI, weight, and weight for 
age Z-score. This is in agreement with the study 
conducted by Teplan et al., who found that serum 
levels of ADMA were negatively correlated with body 
mass index [24]. On the contrary, this finding is not in 
agreement with the study conducted by Kanazawa et 
al., who found significantly positive correlation 
between ADMA and BMI [25]. 
          Moreover our results demonstrated a highly 
significant positive correlation between serum ADMA 
levels and height (r = 0.407; P = 0.009). This is in 
agreement with the study conducted by Faith et al., 
who reported a significant correlation between serum 
ADMA concentration and the height [23]. 
Many studies showed that ADMA is a strong 
and independent predictor of cardiovascular events 
and atherosclerosis [26], and the plasma levels of 
ADMA are increased in conditions associated with 
atherosclerosis, hypertension [27], hypercholestero-
lemia, and hypertriglyceridemia [28].  
In our present study, serum triglycerides and 
total cholesterol levels showed highly significant rise 
in the overweight and obese children when compared 
to the healthy controls (P < 0.000). This is in 
agreement with the study conducted by Sahinarslan et 
al., and Hasanoğlu et al., who reported a relation 
between obesity and high levels of total cholesterol 
and triglycerides [27, 28].  
Our present study also demonstrated a 
significant positive correlation between serum ADMA 
levels and serum total cholesterol (r = 0.317; P = 
0.046), and serum triglycerides (r = 0.371; P = 0.018). 
Serum ADMA levels were significantly higher in 
children with hypertriglyceridemia and 
hypercholesterolemia compared to the healthy 
controls. Linear regression analysis revealed that 
serum triglycerides levels were strong predictors for 
higher risk and associated significantly with high 
serum asymmetric dimethylarginine levels (at p = 
0.015). Kanazawa et al., found a significant positive 
association between ADMA and LDL, HDL and 
cholesterol independent of age [25]. Our findings also 
support the fact that serum ADMA concentration is a 
risk factor for atherosclerosis among children with 
hypertriglyceridemia, and hypercholesterolemia in the 
future [26]. 
Adiponectin has been reported to have anti-
atherogenic properties and protective effects against 
early cardiovascular disease [29]. Weyer et al., have 
demonstrated an association of serum adiponectin 
with adiposity [30]. Reduction of serum adiponectin 
level in some childhood populations was considered 
as a biomarker of obesity and a risk factor for 
developing cardiovascular disease and early 
atherosclerosis [31].  
Our present study revealed that highly 
significant reduction in serum adiponectin levels in the 
overweight and obese children group compared with 
the healthy controls (P = 0.000). This is in agreement 
with the study conducted by Ducluzeau et al., who 
concluded that adiponectin production and 
concentration actually decrease in obese patients 
[32].  
Consistent with Klünder, et al., our present 
study demonstrated insignificant differences in the 
mean serum adiponectin concentrations between 
boys and girls (p > 0.05) [33]. 
Our present study showed a significant 
inverse correlation between serum adiponectin and 
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the anthropometric measures of adiposity in the form 
of weight, BMI, and weight for age Z score, with a P 
value of less than 0.05. This is in agreement with the 
study conducted by Arnaiz et al., who stated that 
adiponectin levels were inversely correlated with 
anthropometric parameters of obesity [34]. Schoppen 
et al., found that adiponectin level was weakly related 
to anthropometric variables in children [35]. A 
negative correlation between serum adiponectin level 
and adiposity has been previously observed in 
Japanese children [36], and a similar negative 
correlation has been reported recently in 5–10 year 
old Pima Indian children [37], as well as in French 
adolescents [38]. These differences may be due to 
racial differences and sociocultural eating habits. 
Our present study demonstrated a significant 
positive correlation between serum adiponectin and 
serum triglycerides levels (r = 0.31; P = 0.049), and no 
significant correlation was present between serum 
adiponectin and serum total cholesterol levels. This is 
in consistent with the findings reported by Klünder et 
al [33]. 
Weyer et al., reported that determination of 
serum adiponectin level in overweight and obese 
children may help in prediction and prevention of 
obesity complications in the future [30]. In our present 
study, linear regression analysis revealed that serum 
adiponectin levels were strong predictors for higher 
risk and associated significantly with high serum 
asymmetric dimethylarginine levels (p = 0.045). 
Furthermore, BMI, weight, height and serum 
triglycerides levels were strong predictors for higher 
risk and associated significantly with low serum 
adiponectin levels (p = 0.005, 0.022, 0.026 and 0.015 
respectively). 
In conclusion, our study demonstrated strong 
associations between hypoadiponectinemia, 
hypercholesterolemia, hypertriglyceridemia, increased 
ADMA levels among overweight and obese Egyptian 
children. Therefore, ADMA, adiponectin, and lipid 
profile can be considered as predictive biomarkers of 
obesity complications.  
Prevention of obesity during childhood is the 
key to the largest possible impact on adult health. 
Evaluation of serum ADMA, adiponectin, cholesterol, 
and triglycerides levels may contribute to reverse the 
rising trend in the incidence of obesity complications 
among overweight and obese children. Further 
studies should be recommended on the larger 
population. Following up of serum adiponectin, 
asymmetric dimethylarginine levels, and lipid profile 
can help in reducing the overall atherosclerotic risk in 
the future. 
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